1. Generics Bulletin
  3. >>Earnings

Hikma Outlines Injectables Growth Amid Slow Start For Generics

Generics Revenues Expected To Be Weighted Towards Second Half Of 2022

 
• By Dave Wallace

Hikma has set out fresh growth forecasts for its injectables business after completing its acquisition of Custopharm. Meanwhile, a slow start to the year for the firm’s generics business amid a “challenging pricing environment” is expected to be followed by higher revenues towards the end of the year.

Growth man drawing graph pen
Hikma has set out its injectables growth expectations after acquiring Custopharm • Source: Christian Horz / Alamy Stock Photo

Hikma says it now expects to achieve global injectables sales growth “in the mid to high-single digits” in 2022, up from previous guidance of low to mid-single digits, after completing its acquisition of Custopharm.

Meanwhile, core operating margin for the year is to be “in the range of 36% to 37%, up from 35%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business